Velico Expands Production Facilities to Meet Plasma Demand Globally

Velico's Major Expansion in Manufacturing and Supply Chain

Beverly, Massachusetts - Velico Medical, Inc. has made headlines with its ambitious plan to expand its manufacturing and supply chain operations. This strategic decision comes as a response to the increasing need for the FrontlineODP™ Spray Dried Plasma Manufacturing System, which is integral for producing dried plasma quickly and efficiently.

The Need for Dried Plasma

The FrontlineODP™ System enables military and civilian blood centers to produce dried plasma from liquid donor plasma in just 30 minutes. This rapid production capability is crucial in emergency situations where immediate blood transfusions can mean the difference between life and death. The dried plasma, stored in lightweight plastic bags, boasts a shelf life of up to two years, ensuring stability and ease of deployment during critical operations.

Upon rehydration, which takes less than three minutes, this plasma can be administered at the point of injury, offering swift and potentially life-saving care for patients suffering from severe bleeding. Such advancements are vital as bleeding emergencies account for a significant number of trauma-related deaths.

A Worldwide Network

Velico's decentralized approach envisions a global network comprising hundreds of blood centers capable of collectively producing tens of thousands of plasma units each year. The anticipated uptake by leading blood centers across North America, Europe, and the Indo-Pacific region is accelerating rapidly, with overall production from installed systems projected to surpass 100,000 units annually.

Commitment to Manufacturing Excellence

In an effort to meet this surging demand, Velico is finalizing plans for new production facilities specifically focused on manufacturing FrontlineODP™ consumables for the European and Indo-Pacific markets. These state-of-the-art facilities will be fully automated and are expected to manufacture up to 250,000 units each year.

When combined with existing production capacities in the United States, Velico's total output could potentially reach nearly one million units of spray-dried plasma annually.

Richard Meehan, President and CEO of Velico, emphasized the importance of this expansion. “For years, Velico has invested heavily in research and development to ensure mass availability of life-saving dried plasma. As global adoption accelerates, we are scaling our manufacturing capabilities to meet unprecedented demand and help reduce deaths from hemorrhage worldwide.”

An Expanding Global Footprint

Andrew Racicot, the newly appointed Vice President of Manufacturing at Velico, added, “Expanding our global manufacturing footprint strengthens Velico's ability to deliver with efficiency, consistency, and quality. This ensures that life-saving plasma is available when and where it’s needed most.”

Velico is committed to becoming a leader in providing innovative solutions for transfusion medicine and emergency care, working closely with civilian and military blood center leaders as well as first responders globally.

Conclusion

As the healthcare landscape continues to evolve, Velico's significant expansion in manufacturing and supply chain operations signals a proactive step towards addressing the critical need for accessible plasma in emergency medical scenarios. With their innovative FrontlineODP™ system, they are set to play a pivotal role in managing trauma effectively and reducing mortality rates associated with hemorrhaging incidents.

>Note: The FrontlineODP™ Spray Dried Plasma System is still investigational and has not yet received regulatory approval for any specific use. Regulatory requirements may vary by region and will dictate the device's approval, clearance, or availability in the market.